Xiao Yanxin, Liu Yan, Zhao Liwei, Zhou Yaru
Department of Endocrinology, The Third Hospital of Hebei Medical University, Shijiazhuang, China.
Department of Endocrinology, Baoding No.1 Central Hospital, Baoding, China.
Metab Syndr Relat Disord. 2022 Oct;20(8):459-465. doi: 10.1089/met.2022.0014. Epub 2022 Aug 4.
The prevalence of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in China, especially in patients with type 2 diabetes mellitus (T2DM). Weight loss strategies have been shown to treat NAFLD effectively. We conducted a 24-week, prospective, randomized study in T2DM patients with NAFLD to evaluate the effects of a 5:2 fasting diet on liver fat content. Sixty-one T2DM patients with NAFLD were enrolled and randomly divided into a 5:2 fasting diet intervention group (5:2 diet group, = 31) and 1.8 mg/day liraglutide intervention group (Lira group, = 30). The study was performed for 24 weeks. Data of the body weight, waist circumference, plasma lipids and glucose profile, fasting plasma insulin, and liver function parameters were collected. Controlled attenuation parameter (CAP) was measured to assess the liver fat content. Superoxide dismutase (SOD) and malondialdehyde (MDA) were measured to evaluate oxidative stress status. At 24 weeks after intervention, compared with those at baseline, CAP was significantly decreased in both the 5:2 diet group and Lira group, which was 7.4% and 5.5%, respectively. Body weight, plasma lipids and glucose profile, and liver function parameters improved significantly, while homeostasis model assessment-β (HOMA-β) was significantly increased in both groups (all < 0.05). Stepwise linear regression showed that increased HOMA-β and SOD, as well as reduced body mass index (BMI), were the independent predictors of CAP decrease in the Lira group ( = 0.000, 0.000, 0.015). In contrast, reduced BMI and MDA were the independent influencing factors of CAP decrease in the 5:2 diet group ( = 0.011, 0.043). The common side effects in the 5:2 diet group were hunger (60%), weakness (10%), and constipation (0.3%). A 5:2 fasting diet achieved comparable effects with liraglutide on liver fat content in patients with T2DM with NAFLD by reducing BMI and oxidative stress. Both treatment strategies were safe and effective for glucose control.
非酒精性脂肪性肝病(NAFLD)在中国的患病率正在迅速上升,尤其是在2型糖尿病(T2DM)患者中。减重策略已被证明能有效治疗NAFLD。我们对患有NAFLD的T2DM患者进行了一项为期24周的前瞻性随机研究,以评估5:2禁食饮食对肝脏脂肪含量的影响。61例患有NAFLD的T2DM患者被纳入研究,并随机分为5:2禁食饮食干预组(5:2饮食组,n = 31)和1.8 mg/天利拉鲁肽干预组(利拉鲁肽组,n = 30)。研究持续24周。收集体重、腰围、血脂和血糖谱、空腹血浆胰岛素及肝功能参数的数据。测量受控衰减参数(CAP)以评估肝脏脂肪含量。测量超氧化物歧化酶(SOD)和丙二醛(MDA)以评估氧化应激状态。干预24周后,与基线时相比,5:2饮食组和利拉鲁肽组的CAP均显著降低,分别降低了7.4%和5.5%。体重、血脂和血糖谱以及肝功能参数显著改善,而两组的稳态模型评估-β(HOMA-β)均显著升高(均P < 0.05)。逐步线性回归显示,HOMA-β和SOD升高以及体重指数(BMI)降低是利拉鲁肽组CAP降低的独立预测因素(P = 0.000、0.000、0.015)。相比之下,BMI和MDA降低是5:2饮食组CAP降低的独立影响因素(P = 0.011、0.043)。5:2饮食组的常见副作用为饥饿(60%)、虚弱(10%)和便秘(0.3%)。5:2禁食饮食通过降低BMI和氧化应激,在患有NAFLD的T2DM患者中对肝脏脂肪含量产生了与利拉鲁肽相当的效果。两种治疗策略对血糖控制均安全有效。